European Society for Medical Oncology (ESMO) 2018 Congress

20181212035900

与他莫昔芬+曲普瑞林联合用药相比，唑来膦酸+来曲唑+曲普瑞林的治疗方案作为激素受体阳性早期乳腺癌的辅助治疗显著改善了患者的无病生存。

KEYNOTE-048: Frontline pembrolizumab ups survival in head and neck cancer

Pearl Toh, 20181119190010

The anti-PD-1 immunotherapy pembrolizumab confers survival benefit over standard chemotherapy in patients with recurrent or metastatic head and neck cancer in the first-line setting, reveals the topline results of the KEYNOTE-048* study presented at ESMO 2018.

Nivolumab-ipilimumab combo shows survival prospects in advanced melanoma

Roshini Claire Anthony, 20181109140306

Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.

Triple-drug combo trumps doublet regimen for biliary tract cancer

Audrey Abella, 20181109100000

The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.

Multistrain probiotics may reduce chemotherapy-induced diarrhoea

Pearl Toh, 20181105180010

Taking a high daily dose multi-strain probiotic may help reduce incidence of mild-to-moderate chemotherapy-induced diarrhoea (CID), a side effect commonly experienced by cancer patients, suggests a randomized study presented at ESMO 2018.

Frontline avelumab + axitinib ups PFS over sunitinib in advanced RCC

Pearl Toh, 20181102110010

Combining the anti-PD-L1 avelumab with the VEGFR* blocker axitinib significantly improves progression-free survival (PFS) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC), according to the JAVELIN Renal 101** trial.

IMpassion 130 heralds in a new era for immunotherapy in breast cancer

Pearl Toh, 20181101190010

Treatment with the PD-L1 inhibitor atezolizumab on top of standard chemotherapy with nab-paclitaxel significantly improves progression-free survival (PFS) in triple-negative breast cancer (TNBC) compared with nab-paclitaxel alone, top-line results from the IMpassion* 130 trial reveal. In particular, median overall survival (OS) was 10 months longer with atezolizumab among PD-L1-positive (PD-L1+) patients in an interim analysis.

Trifluridine-tipiracil combo improves OS in metastatic gastric cancer

Roshini Claire Anthony, 20181101140307

Patients with previously treated metastatic gastric adenocarcinoma had improved overall survival (OS) when a trifluridine-tipiracil combination was added to a supportive care regimen compared with best supportive care alone, according to findings of the phase III TAGS* trial.

Cisplatin remains standard of care for low-risk HPV+ oropharyngeal cancer

Elvira Manzano, 20181101113000

De-escalating therapy falls short of expectations to reduce toxicity in patients with low-risk human papillomavirus-positive (HPV+) oropharyngeal carcinoma, the De-ESCALaTE HPV trial has shown, supporting the current standard of care which is chemotherapy with cisplatin and radiotherapy.

Radiotherapy confers survival benefit for oligometastatic prostate cancer

Audrey Abella, 20181031100000

Adding local radiotherapy (RT) on top of standard of care (SoC) improved overall survival (OS) in men with newly diagnosed oligometastatic (ie, low disease burden [Tany Nany M1]) prostate cancer (PCa), according to the STAMPEDE* trial presented at ESMO 2018.